PMID- 35473583
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220531
IS  - 1755-8794 (Electronic)
IS  - 1755-8794 (Linking)
VI  - 15
IP  - 1
DP  - 2022 Apr 26
TI  - A pancancer analysis of the carcinogenic role of receptor-interacting 
      serine/threonine protein kinase-2 (RIPK2) in human tumours.
PG  - 97
LID - 10.1186/s12920-022-01239-3 [doi]
LID - 97
AB  - BACKGROUND: To explore the expression and carcinogenic mechanism of RIPK2 in 
      human tumours, and to provide the theoretical basis for the further study of 
      RIPK2. METHODS: We used the TCGA, CPTAC, HPA databases to analyse the expression, 
      mutation, and prognosis of RIPK2 in human tumours. Through the Cbioportal, 
      Ualcan, TIMER2.0, and STRING websites, We understand the genetic variation, 
      immune infiltration and enrichment analysis of RIPK2 related genes. RESULTS: 
      RIPK2 was highly expressed in most tumours (such as BRCA, COAD and LUSC, etc.), 
      and the high expression of RIPK2 was correlated with tumour stage and prognosis. 
      In addition, Amplification was the main type of RIPK2 in tumour mutation state, 
      and the amplification rate was about 8.5%. In addition, RIPK2 was positively 
      associated with tumour-infiltrating immune cells (such as CD8+ T, Tregs, and 
      cancer-associated fibroblasts). According to the KEGG analysis, RIPK2 may play a 
      role in tumour mainly through NOD-like signaling pathway and NF-kappaB signaling 
      pathway. GO enrichment analysis showed that the RIPK2 is mainly related to 
      I-kappaB kinase/NF-kappaB signaling, Ribonucleoprotein granule and Ubiquitin-like 
      protein ligase binding. CONCLUSION: RIPK2 plays an important role in the 
      occurrence, development and prognosis of malignant tumours. Our pancancer study 
      provided a relatively comprehensive description of the carcinogenic effects of 
      RIPK2 in different tumours, and provided useful information for further study of 
      RIPK2.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Hanqun
AU  - Zhang H
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, 
      People's Republic of China.
AD  - Department of Oncology, Guizhou Provincial People's Hospital, Guizhou, 550002, 
      People's Republic of China.
FAU - Ma, Yan
AU  - Ma Y
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, 
      People's Republic of China.
FAU - Zhang, Qiuning
AU  - Zhang Q
AD  - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, 
      People's Republic of China.
AD  - University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of 
      China.
AD  - Lanzhou Heavy Ion Hospital, Lanzhou, 730000, People's Republic of China.
FAU - Liu, Ruifeng
AU  - Liu R
AD  - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, 
      People's Republic of China.
AD  - University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of 
      China.
AD  - Lanzhou Heavy Ion Hospital, Lanzhou, 730000, People's Republic of China.
FAU - Luo, Hongtao
AU  - Luo H
AD  - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, 
      People's Republic of China.
AD  - University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of 
      China.
AD  - Lanzhou Heavy Ion Hospital, Lanzhou, 730000, People's Republic of China.
FAU - Wang, Xiaohu
AU  - Wang X
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, 
      People's Republic of China. xhwang@impcas.ac.cn.
AD  - Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, 
      People's Republic of China. xhwang@impcas.ac.cn.
AD  - University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of 
      China. xhwang@impcas.ac.cn.
AD  - Lanzhou Heavy Ion Hospital, Lanzhou, 730000, People's Republic of China. 
      xhwang@impcas.ac.cn.
LA  - eng
PT  - Journal Article
DEP - 20220426
PL  - England
TA  - BMC Med Genomics
JT  - BMC medical genomics
JID - 101319628
RN  - 0 (Carcinogens)
RN  - 0 (NF-kappa B)
RN  - 2ZD004190S (Threonine)
RN  - 452VLY9402 (Serine)
RN  - EC 2.7.11.1 (RIPK2 protein, human)
RN  - EC 2.7.11.1 (Receptor-Interacting Protein Serine-Threonine Kinase 2)
SB  - IM
MH  - Carcinogenesis
MH  - *Carcinogens
MH  - Humans
MH  - NF-kappa B/genetics
MH  - *Neoplasms/genetics
MH  - Receptor-Interacting Protein Serine-Threonine Kinase 2/genetics/metabolism
MH  - Serine
MH  - Threonine
PMC - PMC9040268
OTO - NOTNLM
OT  - Carcinogenesis
OT  - Human tumours
OT  - Mechanism
OT  - Pancancer
OT  - RIPK2
COIS- The authors declare that they have no competing interests, and all authors 
      confirm its accuracy.
EDAT- 2022/04/28 06:00
MHDA- 2022/04/29 06:00
PMCR- 2022/04/26
CRDT- 2022/04/27 05:14
PHST- 2022/01/07 00:00 [received]
PHST- 2022/04/13 00:00 [accepted]
PHST- 2022/04/27 05:14 [entrez]
PHST- 2022/04/28 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
PHST- 2022/04/26 00:00 [pmc-release]
AID - 10.1186/s12920-022-01239-3 [pii]
AID - 1239 [pii]
AID - 10.1186/s12920-022-01239-3 [doi]
PST - epublish
SO  - BMC Med Genomics. 2022 Apr 26;15(1):97. doi: 10.1186/s12920-022-01239-3.